Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib mesylate + recombinant human endostatin
- Development stage
- Unknown
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous
01
Overview
Apatinib mesylate + recombinant human endostatin is a combination therapy used primarily in the treatment of advanced or metastatic cancers, notably non-small cell lung cancer (NSCLC). Apatinib mesylate is an orally administered small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), thereby inhibiting tumor angiogenesis. Recombinant human endostatin is a biologic antiangiogenic agent that inhibits endothelial cell proliferation and migration, further suppressing new blood vessel formation in tumors. The combination has demonstrated improved therapeutic efficacy and immune function with fewer side effects compared to standard chemotherapy in clinical studies for NSCLC[1][7]. Both agents act synergistically to block tumor vascularization and growth.
- Brand names
- AitanEndostar
- Other names
- rivoceranib + recombinant human endostatin
02
Targets
GPC (Lassa virus glycoprotein complex)ITGA5:ITGB1 (Integrin α5β1)αVβ5 (Integrin αVβ5)NCL (Nucleolin)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on apatinib mesylate + recombinant human endostatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib mesylate + recombinant human endostatin.